Why do the same drugs look different? Pills, trade dress, and public health

New England Journal of Medicine

Volumn 365, Issue 1, 2011, Pages 83-89

  Greene, Jeremy A ^a   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE PLUS DEXAMPHETAMINE; COCO QUININE; CYCLANDELATE; ESOMEPRAZOLE; FLUOXETINE; GENERIC DRUG; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; OMEPRAZOLE; PHENTERMINE; PLACEBO; QUIN COCO; QUININE SULFATE; SILDENAFIL; UNCLASSIFIED DRUG;

DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG PACKAGING; FLAVOR; FOOD AND DRUG ADMINISTRATION; LEGAL ASPECT; PATENT; PATIENT COMPLIANCE; PILL; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TRADE DRESS;

EID: 79960108465     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMhle1101722     Document Type: Review

References (52)

1. Generic Pharmaceutical Association. Facts at a glance. (http://www.gphaonline.org/about-gpha/about-generics/facts.)
2. Cutler C, Kesselheim A, Gabardi S, et al. Generic immunosuppressants in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:285-90.
3. Stinson N. Trademarks and "lookalike" drugs. Indiana Law Rev 1982;15:733-64.
4. Newman S. Kill the "mere color" rule: equal protection for color under the Lanham Act. Univ Chic Law Rev 1994;61:1595-626.
5. Lanham Act §43(a), 15 U.S.C. §1125 (2010).
6. TrafFix Devices v. Marketing Displays, 121 S. Ct. 1255 (2001).
7. Brunswick Corp. v. British Seagull, 35 F. 3d 1527 (Fed. Cir. 1994).
8. Warner v. Eli Lilly, 265 U.S. 526 (1924).
9. Norwich Pharmaceutical Company v. Sterling Drug, 271 F.2d 569 (2nd Cir., 1959).
10. Krieg M. Black market medicine. Englewood Cliffs, NJ: Prentice-Hall, 1967.
11. Facchinetti NJ, Dickson WM. Access to generic drugs in the 1950s: the politics of a social problem. Am J Public Health 1982;72:468-75. (Pubitemid 12071071)
12. SK&F Co. v. Premo, 625 F.2d 1055 (3rd Cir., 1980).
13. A.H. Robbins Co. v. Medicine Chest Corp., 1980 U.S. Dist. LEXIS 14412 (E.D. Mo., 1980).
14. Pennwalt v. Zenith Laboratories, 472 F.Supp. 413 (E.D. Mich.1979).
15. Ives v. Darby, 455 F.Supp. 939 (E.D.N.Y., 1978).
16. Inwood v. Ives, 456 U.S. 844 (1982).
17. Greenslit N. Pharmaceutical branding: identity, individuality, and illness. Mol Interv 2002;2:342-5.
18. Fritch DM. Should "the purple pill" by any other drug company still be as purple? The changing face of trade dress protection for pharmaceutical manufacturers. Intellectual Prop Law Rev 2006;51:171-201.
19. Matheson JA, Justus MR. Eye candy. Med Mark Media 2009; 44:55-8.
20. Two Pesos v. Taco Cabana, 505 U.S. 763 (1992).
21. Qualitex Co. v. Jacobson Prods, 514 U.S. 159 (1995).
22. Carpenter DP, Tobbell DA. Bioequivalence: the regulatory history of a scientific concept. Bull Hist Med (in press).
23. Frank RG. The ongoing regulation of generic drugs. N Engl J Med 2007;357:1993-6. (Pubitemid 350106706)
24. Kirsche ML. Generic substitution spells big money for retail pharmacy. Drug Store News. August 22, 2005.
25. Shire v. Barr, 329 F.3d 348 (3rd Cir., 2003).
26. Wal-Mart Stores v. Samara Bros., 529 U.S. 205 (2000).
27. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009;43:1583-97.
28. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2009;300:2514-26.
29. Kohn LT, Corrigan J, Donaldson MS, eds. To err is human: building a safer health system. Washington, DC: National Academies Press, 2000.
30. Glaxo whistle-blower lawsuit: bad medicine. CBS 60 Minutes. December 29, 2010. (http://www.cbsnews.com/stories/2010/12/29/60minutes/main7195247-page2. shtml.)
31. Kenagy JW, Stein GC. Naming, labeling, and packaging of pharmaceuticals. Am J Health Syst Pharm 2001;58:2033-41. (Pubitemid 33043387)
32. Schiff GD. Standardized pill imprint codes: a pharma fantasy. J Med Syst 2004;28:1-7.
33. Ngoh LN. Health literacy: a barrier to pharmacist-patient communication and medication adherence. J Am Pharm Assoc 2009;49(5):e132-e146.
34. Levinthal BR, Morrow DG, Tu W, Wu J, Murray MD. Cognition and health literacy in patients with hypertension. J Gen Intern Med 2008;23:1172-6.
35. Cárdenas-Valladolid J, Martín-Madrazo C, Salinero-Fort MA, Carrillo de-Santa Pau E, Abánades-Herranz JC, de Burgos-Lunar C. Prevalence of adherence to treatment in homebound elderly people in primary health care: a descriptive, cross-sectional, multicentre study. Drugs Aging 2010;27:641-51.
36. Wolf MS, Curtis LM, Waite K, et al. Helping patients simplify and safely use complex prescription regimens. Arch Intern Med 2011;171:300-5.
37. Hellier E, Tucker M, Kenny N, Rowntree A, Edworthy J. Merits of using color and shape differentiation to improve the speed and accuracy of drug strength identification on over-the-counter medicines by laypeople. J Patient Saf 2010;6:158-64.
38. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003.
39. Greene JA. Prescribing by numbers: drugs and the definition of disease. Baltimore: Johns Hopkins University Press, 2007.
40. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007;357:673-81. (Pubitemid 47267237)
41. Huskisson E. Simple analgesics for arthritis. Br Med J 1974; 4:196-200.
42. Lucchelli PE, Cattaneo AD, Zattoni J. Effect of capsule colour and order of administration of hypnotic treatments. Eur J Clin Pharmacol 1978;13:153-5. (Pubitemid 8346376)
43. Harrington A. The placebo effect. Cambridge, MA: Harvard University Press, 1997.
44. Jacobs KW, Nordan FM. Classification of placebo drugs: effect of color. Percept Mot Skills 1979;49:367-72.
45. de Craen AJ, Roos PJ, Leonard de Vries A, Kleijnen J. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ 1996;313:1624-6. (Pubitemid 27010670)
46. Khan A, Bomminayuni EP, Bhat A, Faucett J, Brown WA. Are the colors and shapes of current psychotropics designed to maximize the placebo response? Psychopharmacology (Berl) 2010;211:113-22.
47. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA 2008;299:1016-7. (Pubitemid 351347074)
48. Lambert BL, Lin SJ, Tan H. Designing safe drug names. Drug Saf 2005;28:495-512. (Pubitemid 41003055)
49. Shrank WH, Choudhry NK, Agnew-Blais J, et al. State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood) 2010;29:1383-90.
50. Horn CR, Cochrane GM. Colour coding for bronchodilator inhalers. Lancet 1986;1:165. (Pubitemid 16183146)
51. Gray S. Asthma inhaler devices. In: NHS evidence - respiratory. (http://www.library.nhs.uk/respiratory/viewresource.aspx?resid=125010.)
52. Berman A. Reducing medication errors through naming, labeling, and packaging. J Med Syst 2004;28:9-29. (Pubitemid 39012178)